Decision means none of drugmaker’s much-trumpeted £650m UK investment package is currently proceeding
The drugmaker AstraZeneca has paused a planned £200m expansion of its Cambridge research site, completing a depressing week for the UK pharmaceutical industry.
The decision by the UK’s largest company means none of its much-trumpeted £650m investment package in the UK – which was originally announced in March 2024 – is proceeding.
Continue reading...
